Taking in the trash: bioreactors for the mass production of clinical-grade extracellular vesicles

References

[1] Chistiakov DA,Bobryshev YV.Cardiac extracellular vesicles in normal and infarcted heart.Int J Mol Sci2016;17:63 PMCID:PMC4730308

[2] Rashed MH,Helal GK.Exosomes: from garbage bins to promising therapeutic targets.Int J Mol Sci2017;18:538 PMCID:PMC5372554

[3] Zhang Y,Zheng L.Characteristics and roles of exosomes in cardiovascular disease.DNA Cell Biol2017;36:202-11

[4] Zhang L.Exosomes in cancer development, metastasis, and immunity.Biochim Biophys Acta Rev Cancer2019;1871:455-68 PMCID:PMC6542596

[5] Bei Y,Lv D.Exercise-induced circulating extracellular vesicles protect against cardiac ischemia-reperfusion injury.Basic Res Cardiol2017;112:38 PMCID:PMC5748384

[6] Vogt S,Grillari J,Wozniak-knopp G.Engineering of surface proteins in extracellular vesicles for tissue-specific targeting. In: Shiomi N, editor. Current topics in biochemical engineering. IntechOpen; 2019.

[7] Bergmann O,Bernard S.Evidence for cardiomyocyte renewal in humans.Science2009;324:98-102 PMCID:PMC2991140

[8] Hatzistergos KE,Oskouei BN.Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation.Circ Res2010;107:913-22 PMCID:PMC3408082

[9] Molkentin JD.Letter by Molkentin regarding article, "The absence of evidence is not evidence of absence: the pitfalls of Cre Knock-Ins in the c-Kit Locus".Circ Res2014;115:e21-3 PMCID:PMC4278750

[10] Bolli R,Hare JM.Cardiovascular Cell Therapy Research Network (CCTRN)A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial.Eur J Heart Fail2021;23:661-74 PMCID:PMC8357352

[11] Zhu X,Pomeroy S.Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells.J Extracell Vesicles2017;6:1324730 PMCID:PMC5505007

[12] Colao IL,Bracewell D.Manufacturing exosomes: a promising therapeutic platform.Trends Mol Med2018;24:242-56

[13] Bellio MA,Takeuchi L.Systemic delivery of large-scale manufactured Wharton’s Jelly mesenchymal stem cell-derived extracellular vesicles improves cardiac function after myocardial infarction.J Cardiovasc Aging2022;

[14] Liang Y,Li X.Chondrocyte-targeted microRNA delivery by engineered exosomes toward a cell-free osteoarthritis therapy.ACS Appl Mater Interfaces2020;12:36938-47

[15] Cheng H,Xu R.Hypoxia-challenged MSC-derived exosomes deliver miR-210 to attenuate post-infarction cardiac apoptosis.Stem Cell Res Ther2020;11:224 PMCID:PMC7278138

[16] Chen J,Cheng Y.Mesenchymal stem cell-derived exosomes protect beta cells against hypoxia-induced apoptosis via miR-21 by alleviating ER stress and inhibiting p38 MAPK phosphorylation.Stem Cell Res Ther2020;11:97 PMCID:PMC7055095